2/8/2007 | PP | Market Commentary: Cell Therapeutics secures $17.6 million from placement; Genelabs to close $10 million stock offering
|
2/7/2007 | PP | New Issue: Gentium to sell $47.5 million of American Depositary Shares
|
2/7/2007 | PP | Market Commentary: Gentium to close $47.48 million stock sale; RSX Energy plans C$10.03 million offering
|
9/5/2006 | BT | Gentium says Defibrotide may prevent endothelial complications
|
8/15/2006 | BT | Gentium says revenues for second-quarter, first half of 2006 are up
|
7/11/2006 | BT | Gentium's Defibrotide for pediatric VOD yields positive survival, safety results in two separate studies
|
6/1/2006 | BT | Market Commentary: Targeted Genetics' stock jumps 18% on promising data; Endologix raises $20.13 million from stock sale
|
6/1/2006 | PP | Market Commentary: Endologix secures $20.13 million from direct stock deal; Numerex raises $10 million from notes
|
5/31/2006 | BTPP | New Issue: Gentium secures $22.13 million from private placement of ADS
|
5/31/2006 | BT | Market Commentary: Gentium gains on PIPE; Cubist holders await convertible smoke to clear; Crucell up; Durect higher
|
5/31/2006 | PP | Market Commentary: Italy's Gentium secures $22.13 million from PIPE; Isonics raises $16 million from convertibles
|
5/18/2006 | BT | Gentium 1Q revenues up, company reports loss per share of €0.32
|
5/5/2006 | BT | Gentium to trade on Nasdaq
|
4/13/2006 | BT | Gentium says loss hits €12.43 million in 2005, predicts 'significantly larger' loss in 2006
|
3/28/2006 | BT | Gentium gets board OK to start phase 3 trial of Defibrotide for veno-occlusive disease
|
2/2/2006 | BT | Gentium's Defibrotide in multiple trials for vascular disease, cancer
|
1/20/2006 | BT | Gentium starts phase 2/3 pediatric trial with Defibrotide to prevent veno-occlusive disease
|
12/7/2005 | BT | Gentium's Defibrotide increases veno-occlusive disease survival rate, study says
|
10/4/2005 | PP | Market Commentary: Whitehall Jewellers raises $50 million; Matrix Service stock up after $14.9 million PIPE deal
|
10/4/2005 | BTPP | New Issue: Gentium raises $10.93 million in private placement of ADS
|
7/27/2005 | BT | Gentium greenshoe partially exercised, lifting ADS offering to $24.3 million
|
6/20/2005 | BT | Market Commentary: HemoSense cuts IPO range; Impax labs, Xoma gain on credit fronts; ImClone up on drug plans
|
6/16/2005 | BT | New Issue: Gentium prices downsied $21.6 million IPO at $9 per share, at low end of range
|
6/16/2005 | BT | Market Commentary: Pfizer purchase spurs speculative buying; Cubist advances; ev3, Micrus, Gentium IPOs discounted
|